These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 29735826

  • 1. Cytomegalovirus reactivation and disease amongst patients with allogeneic haematopoietic stem cell transplantation in Eastern India: Epidemiology, outcome and healthcare cost.
    Kumar M, Roychowdhury M, Kumar J, Harishankar A, Sinha S, Bhave SJ, Chakrapani A, Radhakrishnan V, Nair R, Bhattacharya S, Chandy M.
    Indian J Med Microbiol; 2018; 36(1):49-53. PubMed ID: 29735826
    [Abstract] [Full Text] [Related]

  • 2. Cytomegalovirus reactivation following hematopoietic stem cell transplantation.
    Sharma SK, Kumar S, Agrawal N, Singh L, Mukherjee A, Seth T, Mishra P, Mathur S, Dar L, Mahapatra M.
    J Infect Dev Ctries; 2013 Dec 15; 7(12):1003-7. PubMed ID: 24334950
    [Abstract] [Full Text] [Related]

  • 3. Low-dose valgancyclovir as cytomegalovirus reactivation prophylaxis in allogeneic haematopoietic stem cell transplantation.
    Serio B, Rosamilio R, Giudice V, Pepe S, Zeppa P, Esposiito S, Pezzullo L, Rocco M, Montuori N, Selleri C.
    Infez Med; 2012 Dec 15; 20 Suppl 2():26-34. PubMed ID: 23042003
    [Abstract] [Full Text] [Related]

  • 4. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.
    Busca A, de Fabritiis P, Ghisetti V, Allice T, Mirabile M, Gentile G, Locatelli F, Falda M.
    Transpl Infect Dis; 2007 Jun 15; 9(2):102-7. PubMed ID: 17461994
    [Abstract] [Full Text] [Related]

  • 5. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K.
    Transpl Infect Dis; 2010 Aug 01; 12(4):322-9. PubMed ID: 20487414
    [Abstract] [Full Text] [Related]

  • 6. Factors associated with cytomegalovirus infection in children undergoing allogeneic hematopoietic stem-cell transplantation.
    Jaing TH, Chang TY, Chen SH, Wen YC, Yu TJ, Lee CF, Yang CP, Tsay PK.
    Medicine (Baltimore); 2019 Jan 01; 98(4):e14172. PubMed ID: 30681583
    [Abstract] [Full Text] [Related]

  • 7. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.
    Boeckh M, Nichols WG, Chemaly RF, Papanicolaou GA, Wingard JR, Xie H, Syrjala KL, Flowers ME, Stevens-Ayers T, Jerome KR, Leisenring W.
    Ann Intern Med; 2015 Jan 06; 162(1):1-10. PubMed ID: 25560711
    [Abstract] [Full Text] [Related]

  • 8. Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission.
    Yoon JH, Lee S, Kim HJ, Jeon YW, Lee SE, Cho BS, Lee DG, Eom KS, Kim YJ, Min CK, Cho SG, Min WS, Lee JW.
    Oncotarget; 2016 Mar 29; 7(13):17230-41. PubMed ID: 26883100
    [Abstract] [Full Text] [Related]

  • 9. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
    Almyroudis NG, Jakubowski A, Jaffe D, Sepkowitz K, Pamer E, O'Reilly RJ, Papanicolaou GA.
    Transpl Infect Dis; 2007 Dec 29; 9(4):286-94. PubMed ID: 17511819
    [Abstract] [Full Text] [Related]

  • 10. Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.
    Dwabe S, Hsiao M, Ali A, Rodman J, Savitala-Damerla L, Nazaretyan S, Kimberly Schiff NP, Tam E, Ladha A, Woan K, Chaudhary P, Yaghmour G.
    Transpl Immunol; 2023 Feb 29; 76():101769. PubMed ID: 36464218
    [Abstract] [Full Text] [Related]

  • 11. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation.
    Montesinos P, Sanz J, Cantero S, Lorenzo I, Martín G, Saavedra S, Palau J, Romero M, Montava A, Senent L, Martínez J, Jarque I, Salavert M, Córdoba J, Gómez L, Weiss S, Moscardó F, de la Rubia J, Larrea L, Sanz MA, Sanz GF.
    Biol Blood Marrow Transplant; 2009 Jun 29; 15(6):730-40. PubMed ID: 19450758
    [Abstract] [Full Text] [Related]

  • 12. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, Kanamori H, Miyamura K, Kato C, Kobayashi N, Uchida N, Nakamae H, Ichinohe T, Morishima Y, Suzuki R, Yamaguchi T, Fukuda T.
    Biol Blood Marrow Transplant; 2015 Nov 29; 21(11):2008-16. PubMed ID: 26211985
    [Abstract] [Full Text] [Related]

  • 13. Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients.
    Oppenheimer F, Gonzalez-Molina M, Rubio M.
    Clin Transplant; 2007 Nov 29; 21(4):441-8. PubMed ID: 17645702
    [Abstract] [Full Text] [Related]

  • 14. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
    Gerbase MW, Dubois D, Rothmeier C, Spiliopoulos A, Wunderli W, Nicod LP.
    Chest; 1999 Nov 29; 116(5):1265-72. PubMed ID: 10559085
    [Abstract] [Full Text] [Related]

  • 15. Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade II-IV acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: JSTCT Transplant Complications Working Group.
    Kimura SI, Tamaki M, Okinaka K, Seo S, Uchida N, Igarashi A, Ozawa Y, Ikegame K, Eto T, Tanaka M, Shiratori S, Nakamae H, Sawa M, Kawakita T, Onizuka M, Fukuda T, Atsuta Y, Kanda Y, Nakasone H.
    Ann Hematol; 2021 Dec 29; 100(12):3029-3038. PubMed ID: 34490500
    [Abstract] [Full Text] [Related]

  • 16. Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir.
    Bedel AN, Hemmelgarn TS, Kohli R.
    Liver Transpl; 2012 Mar 29; 18(3):347-54. PubMed ID: 22139888
    [Abstract] [Full Text] [Related]

  • 17. Oral Valganciclovir as Preemptive Therapy for Cytomegalovirus Reactivation in Pediatric Hematopoietic Stem Cell Transplant Patients.
    Atay D, Erbey F, Akcay A, Dag A, Ozturk G.
    J Pediatr Hematol Oncol; 2015 Oct 29; 37(7):543-7. PubMed ID: 26207778
    [Abstract] [Full Text] [Related]

  • 18. Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients.
    Johansson I, Mårtensson G, Nyström U, Nasic S, Andersson R.
    BMC Infect Dis; 2013 Dec 10; 13():582. PubMed ID: 24325216
    [Abstract] [Full Text] [Related]

  • 19. The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation.
    Wilhelm K, Chemaly R, Saliba R, Gulbis A, Saunders I, Cool R, Ferguson J, Westmoreland M, Rondon G, Kebriaei P.
    J Oncol Pharm Pract; 2014 Aug 10; 20(4):257-62. PubMed ID: 24022408
    [Abstract] [Full Text] [Related]

  • 20. Incidence and risk factors for cytomegalovirus (CMV) reactivation following autologous hematopoietic stem cell transplantation in children.
    Hussein AA, Al-Antary ET, Najjar R, Al-Hamdan DS, Al-Zaben A, Frangoul H.
    Pediatr Blood Cancer; 2015 Jun 10; 62(6):1099-101. PubMed ID: 25346146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.